ARCHIVES

ODAC Recommends Approval of Evista for Breast Cancer Risk Reduction.

This article is from The Cancer Letter archive.

Vol. 33 No. 29 | July 27, 2007

Download PDF Visit The Full Archive

Related Articles

NIH Limits Salaries On Grants, Contracts ACS Clinical Awards Available For 1995

February 25, 1994

Sharfstein To Leave FDA

January 7, 2011

DeVita’s “Radical” Statement – Resectability Rate Should Be The Cure Rate

October 1, 1976

NIH Biennial Report Offers Research Portrait

September 24, 2010

In Brief: ACA Executive Committee Votes to Move HQ Out Of New York; Davis Establishes Office In D.C.

April 17, 1987

Genentech: ODAC Lacks Expertise, Impartiality; FDA: Company’s Proposal Unscientific

August 12, 2011